Abstract: Scleroderma is a group of autoimmune diseases characterized by thickening and hardening of skin lesions. It involves a wide range of tissues and organs, and various mechanisms of pathogenesis. At present, drugs with established effects are lacking for the treatment of scleroderma. Immunosuppression, anti-fibrosis and symptomatic supportive therapy are often used in the treatment of scleroderma. Recently, some new drugs for vascular diseases and some biological agents have been gradually applied in scleroderma, providing new opportunities for treatment. The guidelines for the treatment of scleroderma has also been constantly updated and improved in recent years, which is conducive to the early evaluation and systematic treatment of scleroderma.